Why Neurocrine Biosciences Stock Was Tumbling This Week

The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea. Neurocrine Biosciences (NBIX 3.77%) had some major news to report several days ago, but it was hardly beneficial to the company's stock. The latest information from the lab dampened enthusiasm for the company, sending its share price down by 16% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. One clear success out of four B ...